Serenoa repens/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases nocturnal voiding frequency (nocturia)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Placebo was associated with a reduction in the mean number of nocturnal voids of 0.63 (0.14); there was a further reduction attributable to Permixon of 0.38 (0.07) (P < 0.001).”
Quoted verbatim from Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.. - Study
- meta-analysis
- Population
- Men with symptomatic BPH; pooled analysis of 14 randomized and 3 open-label Permixon trials (total N=4280) vs placebo
Effect 0.38 mean difference
Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.2004PMID:15049985Permalink
Keep reading
- Everything the graph holds on Serenoa repens
- Every compound studied against Nocturnal voiding frequency (nocturia)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M1G0QF5C7FF14Z4ZHQFS2889